Elucidation of the interaction between Akt and Runx2 in the regulation of cell size, chemotaxis, and differentiation of skeletal component cells
Elucidation of the interaction between Akt and Runx2 in the regulation of cell size, chemotaxis, and differentiation of skeletal component cells
批准号:
15370087
负责人:
KOMORI Toshihisa
金额:
$9.86万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We analyzed the crosstalk between Runx2 and phosphatidylinositol 3-kinase (PI3K)-Akt signaling in the differentiation and chemotaxis of osteoblasts and chondrocytes. Both Runx2 and PI3K-Akt signaling enhanced osteoblast differentiation and chemotaxis in C3H10T1/2 cells and MC3T3-E1 cells, and enhanced chondrogenic differentiation and further maturation in ATDC5 cells. Runx2 upregulated p85, p110β, and Akt proteins, and PI3K-Akt signaling enhanced and dominant negative(dn)Akt suppressed the capacities of Runx2 for DNA binding and transcriptional activation. Therefore, Runx2 and PI3K-Akt signaling crosstalk and enhance osteoblast and chondrocyte differentiation. However, Akt was not involved in the phosphorylation of Runx2. Thus, it is considered that Akt modulates Runx2 function by the phosphorylation of the proteins that form a complex with Runx2. Statin suppressed chemotaxis of osteoblasts by inhibiting Rac-Akt signaling.Dexamethazon(DEX) inhibited the aggregation of ATDC5 cells, which is the first step for the chondrogenic differentiation. Runx2 and Akt enhanced aggregation of ATDC5 cells, while dn-Runx2 and dn-Akt inhibited the aggregation. DEX suppressed phosphrylation of Akt, the level of PI3K subunit proteins, p85 and p110,and the capacity of Runx2 for the DNA binding and transcriptional activation. Thus, DEX inhibits the aggregation of ATDC5 cells by suppressing Akt phosphoorylation, which is followed by the inhibition of DNA binding of Runx2 and Runx2-dependet transcription leading to the decrease in p85 and p110 proteins.
期刊论文(92)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.bbrc.2004.01.104
发表时间:
2004-03-12
期刊:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:
3.1
作者:
[Fukuyama, R, Fujita, T, Komori, T]
通讯作者:
Komori, T
DOI:
10.1007/s00429-004-0393-2
发表时间:
2004-07-01
期刊:
ANATOMY AND EMBRYOLOGY
影响因子:
--
作者:
[Shibata, S, Suda, N, Komori, T]
通讯作者:
Komori, T
T.Komori: "Requisite roles of Runx2 and Cbfb in skeletal development"J.Bone Miner.Metab.. 21. 193-197 (2003)
T.Komori:“Runx2 和 Cbfb 在骨骼发育中的必要作用”J.Bone Miner.Metab.. 21. 193-197 (2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia.
牙本质基质蛋白 1 在导致致癌性骨软化的肿瘤中的表达。
DOI:
--
发表时间:
2004
期刊:
Modern Pathol. 17
影响因子:
--
作者:
[S.Toyosawa]
通讯作者:
S.Toyosawa
DOI:
10.1101/gad.1284605
发表时间:
2005-03-01
期刊:
GENES & DEVELOPMENT
影响因子:
10.5
作者:
[Isono, K, Mizutani-Koseki, Y, Koseki, H]
通讯作者:
Koseki, H
共 40 条
Elucidation of the mechanism of the regulation of Col1a1 gene expression by Runx2
-
批准号:18K19654
-
项目类别:Grant-in-Aid for Challenging Research (Exploratory)
-
资助金额:$4.08万
-
财政年份:2018
-
负责人:KOMORI Toshihisa
-
依托单位:
Identification of the target genes of glucocorticoid receptor in the pathogenesis of steroid-induced osteoporosis
-
批准号:16K15781
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.25万
-
财政年份:2016
-
负责人:KOMORI Toshihisa
-
依托单位:
Elucidation of the pathogenesis of disuse osteoporosis and steroid-induced osteoporosis using Fkbp5 knockout mice
-
批准号:26670811
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2014
-
负责人:KOMORI Toshihisa
-
依托单位:
Elucidation of the transcriptional regulation of Runx2 and development of the drugs for osteoporosis and osteoarthritis
-
批准号:26221310
-
项目类别:Grant-in-Aid for Scientific Research (S)
-
资助金额:$124.8万
-
财政年份:2014
-
负责人:KOMORI Toshihisa
-
依托单位:
Identification and functional analysis of a novel substrate of Pdk4 in the regulation of osteoclastogenesis in the unloaded condition
-
批准号:24659829
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2012
-
负责人:KOMORI Toshihisa
-
依托单位:
The molecule mechanism of the bone mass regulation by a bone cell network
-
批准号:22659331
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.05万
-
财政年份:2010
-
负责人:KOMORI Toshihisa
-
依托单位:
The mechanism of transcriptional regulation of Runx2 gene and the program of skeletal development
-
批准号:22249062
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$30.37万
-
财政年份:2010
-
负责人:KOMORI Toshihisa
-
依托单位:
Elucidation of the mechanism of skeletal development using Runx2 and Cbfb conditional knockout mice
-
批准号:19390465
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.31万
-
财政年份:2007
-
负责人:KOMORI Toshihisa
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于“痞积转化”理论探究网果酸模通过PI3K/Akt通路调控巨噬细胞极化平衡抑制胃癌的分子机制
-
批准号:JCZRLH202601927
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
“补肾健脾,化痰通络”法调控PI3K/Akt/MCT1介导的乳酸转运改善血管性痴呆的机制研究
-
批准号:JCZRLH202600974
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
葛根素通过调控PI3K/Akt介导的代谢重编程抑制心肌梗死后心脏纤维化的机制研究
-
批准号:2026JJ80327
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张婷
-
依托单位:
金荞麦黄酮靶向抑制c-MET介导的PI3K/Akt和Ras/MAPK通路逆转NSCLC EGFR-TKI耐药的机制研究
-
批准号:2026JJ81256
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李弘德
-
依托单位:
基于PI3K/Akt信号通路探索气道炎症在慢性阻塞性肺疾病中的作用及培元固肺膏干预研究
-
批准号:2026JJ82022
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘丹
-
依托单位:
基于PI3K/Akt信号通路探讨钩大青酮调控BGN-COL1A1轴抑制结肠癌侵袭与迁移的机制研究
-
批准号:2026JJ82464
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陆文洪
-
依托单位:
成纤维细胞中NR2F1-AS1协同KRAS通过PI3K/AKT/mTOR途径促进胰腺导管腺癌发展
-
批准号:2026JJ82537
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周小兵
-
依托单位:
基于PI3K/Akt/mTOR信号通路介导的细胞自噬探讨参芪通痹胶囊治疗虚瘀证糖尿病周围神经病变的作用机制研究
-
批准号:2026JJ81891
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:潘娟
-
依托单位:
CSTA通过PI3K/AKT/mTOR通路调控角质形成细胞自噬-凋亡平衡在糖尿病足溃疡复发中的作用及机制研究
-
批准号:2026JJ81911
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:许云华
-
依托单位:
力学响应干细胞外囊泡通过Sclerostin/PI3K/AKT轴促进骨腱界面损伤愈合的作用机制研究
-
批准号:2026JJ50337
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖汉
-
依托单位: